351 related articles for article (PubMed ID: 16127046)
41. Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures.
Jiang ZG; Cohen J; Marshall LJ; Major EO
Antimicrob Agents Chemother; 2010 Nov; 54(11):4723-32. PubMed ID: 20823288
[TBL] [Abstract][Full Text] [Related]
42. Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro.
van der Strate BW; De Boer FM; Bakker HI; Meijer DK; Molema G; Harmsen MC
Antiviral Res; 2003 Apr; 58(2):159-65. PubMed ID: 12742576
[TBL] [Abstract][Full Text] [Related]
43. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase.
Xiong X; Smith JL; Kim C; Huang ES; Chen MS
Biochem Pharmacol; 1996 Jun; 51(11):1563-7. PubMed ID: 8630098
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and Ativiral Activity of 5-(Benzylthio)-4-carbamyl-1,2,3-triazoles Against Human Cytomegalovirus (CMV) and Varicella-zoster Virus (VZV).
Wen YN; Zhang ZF; Liu NN; Andrei G; Snoeck R; Xiang YH; Schols D; Chen X; Zhang ZY; Zhang QS; Wu QP
Med Chem; 2017; 13(5):453-464. PubMed ID: 28290250
[TBL] [Abstract][Full Text] [Related]
45. Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.
Stals FS; de Clercq E; Bruggeman CA
Antimicrob Agents Chemother; 1991 Nov; 35(11):2262-6. PubMed ID: 1666493
[TBL] [Abstract][Full Text] [Related]
46. Antiviral activity of brincidofovir on parvovirus B19.
Bua G; Conti I; Manaresi E; Sethna P; Foster S; Bonvicini F; Gallinella G
Antiviral Res; 2019 Feb; 162():22-29. PubMed ID: 30529090
[TBL] [Abstract][Full Text] [Related]
47. A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors.
Bedard J; May S; Barbeau D; Yuen L; Rando RF; Bowlin TL
Antiviral Res; 1999 Feb; 41(1):35-43. PubMed ID: 10321577
[TBL] [Abstract][Full Text] [Related]
48. (Z)- and (E)-2-(hydroxymethylcyclopropylidene)-methylpurines and pyrimidines as antiviral agents.
Qiu YL; Ptak RG; Breitenbach JM; Lin JS; Cheng YC; Kern ER; Drach JC; Zemlicka J
Antivir Chem Chemother; 1998 Jul; 9(4):341-52. PubMed ID: 9875413
[TBL] [Abstract][Full Text] [Related]
49. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation.
Xiong X; Smith JL; Chen MS
Antimicrob Agents Chemother; 1997 Mar; 41(3):594-9. PubMed ID: 9055999
[TBL] [Abstract][Full Text] [Related]
50. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.
Tan HH; Goh CL
Am J Clin Dermatol; 2006; 7(1):13-29. PubMed ID: 16489840
[TBL] [Abstract][Full Text] [Related]
51. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.
De Clercq E; Naesens L; De Bolle L; Schols D; Zhang Y; Neyts J
Rev Med Virol; 2001; 11(6):381-95. PubMed ID: 11747000
[TBL] [Abstract][Full Text] [Related]
52. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1.
Maggs DJ; Clarke HE
Am J Vet Res; 2004 Apr; 65(4):399-403. PubMed ID: 15077679
[TBL] [Abstract][Full Text] [Related]
53. Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique.
Snoeck R; Schols D; Andrei G; Neyts J; De Clercq E
Antiviral Res; 1991 Jul; 16(1):1-9. PubMed ID: 1663725
[TBL] [Abstract][Full Text] [Related]
54. Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections.
Kern ER; Rybak RJ; Hartline CB; Bidanset DJ
Antivir Chem Chemother; 2001; 12 Suppl 1():149-56. PubMed ID: 11594682
[TBL] [Abstract][Full Text] [Related]
55. In vitro antiviral activity of aphidicolin and its derivates. Synergistic effects of aphidicolin with other antiviral drugs.
Michaelis M; Langer K; Vogel JU; Kreuter J; Rabenau H; Doerr HW; Cinatl J
Arzneimittelforschung; 2002; 52(5):393-9. PubMed ID: 12087926
[TBL] [Abstract][Full Text] [Related]
56. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.
Florescu DF; Keck MA
Expert Rev Anti Infect Ther; 2014 Oct; 12(10):1171-8. PubMed ID: 25120093
[TBL] [Abstract][Full Text] [Related]
57. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.
Herget T; Freitag M; Morbitzer M; Kupfer R; Stamminger T; Marschall M
Antimicrob Agents Chemother; 2004 Nov; 48(11):4154-62. PubMed ID: 15504835
[TBL] [Abstract][Full Text] [Related]
58. Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents.
Thomsen DR; Oien NL; Hopkins TA; Knechtel ML; Brideau RJ; Wathen MW; Homa FL
J Virol; 2003 Feb; 77(3):1868-76. PubMed ID: 12525621
[TBL] [Abstract][Full Text] [Related]
59. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
Kornbluth RS; Smee DF; Sidwell RW; Snarsky V; Evans DH; Hostetler KY
Antimicrob Agents Chemother; 2006 Dec; 50(12):4038-43. PubMed ID: 16982794
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.
Prichard MN; Quenelle DC; Hartline CB; Harden EA; Jefferson G; Frederick SL; Daily SL; Whitley RJ; Tiwari KN; Maddry JA; Secrist JA; Kern ER
Antimicrob Agents Chemother; 2009 Dec; 53(12):5251-8. PubMed ID: 19770274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
